Dominic G. Piscitelli sold $2.25M worth of shares in AnaptysBio, Inc. in December 2018
Jan 08, 2019
Chief Financial Officer & Principal Accounting Officer at ORIC Pharmaceuticals, Inc.
In The News
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
Jun 28, 2021 - GlobeNewswire
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
Jun 02, 2021 - GlobeNewswire
May 26, 2021 - GlobeNewswire
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
In The News
May 27, 2021 - GlobeNewswire
May 09, 2021 - Nasdaq
Apr 22, 2021 - GlobeNewswire